Drug discovery compact agreed between Gilead and Trianni

Californian biotech firms Gilead Sciences (Nasdaq: GILD) and Trianni have entered into a license agreement to leverage the latter’s proprietary drug discovery platform.

The deal will see the firms make use of the transgenic human monoclonal antibody discovery platform to look for new human antibodies and develop new therapies in areas of unmet medical need.

Trianni chief executive Matthias Wabl said: "We are confident that the cutting-edge genomic design of the Trianni discovery platform, which combines the complete human antibody repertoire with wild-type mouse immune responses to any target antigen, will nicely complement Gilead’s drug discovery programs."